A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

被引：2
|
作者：
Chen, Jiaying
Ji, Qinghai
Cao, Junning
Ji, Dongmei
Bai, Chunmei
Lin, Yansong
Pan, Bin
Sun, Guofang
Li, Jing
Qi, Chuan
Hua, Ye
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Phase Unit, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC)
    Carr, L.
    Goulart, B.
    Martins, R.
    Keith, E.
    Kell, E.
    Wallace, S.
    Capell, P.
    Mankoff, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
    Brose, Marcia S.
    Capdevila, Jaume
    Elisei, Rossella
    Bastholt, Lars
    Fuehrer-Sakel, Dagmar
    Leboulleux, Sophie
    Sugitani, Iwao
    Taylor, Matthew H.
    Wang, Zhuoying
    Wirth, Lori J.
    Worden, Francis P.
    Bernard, John
    Caferra, Paolo
    Colzani, Raffaella M.
    Liu, Shiguang
    Schlumberger, Martin
    ENDOCRINE-RELATED CANCER, 2024, 31 (08)
  • [33] Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease
    Mischler, Katharina
    Kneifel, Stefan
    Cathomas, Richard
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (09) : 548 - 552
  • [34] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON AND SURVIVAL EXTRAPOLATION IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-REFRACTORY DTC): UPDATED ANALYSIS
    Tremblay, G.
    Pelletier, C.
    Forsythe, A.
    Majethia, U.
    VALUE IN HEALTH, 2015, 18 (07) : A435 - A435
  • [35] Panobinostat, a Novel Histone Deacetylase Inhibitor, in Metastatic Medullary Thyroid Cancer and Iodine-refractory Differentiated Thyroid Cancer
    Murray, S. E.
    Traynor, A. M.
    Leverson, G. E.
    Elson, D. F.
    Hernan, H. R.
    Larson, M. M.
    Blank, J. H.
    Chen, H.
    Sippel, R. S.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S83 - S83
  • [36] Assessment of second-line VEGF-inhibitor therapy in radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC).
    Dunn, Lara
    Ho, Alan Loh
    Haque, Sofia
    Fury, Matthew G.
    Baxi, Shrujal S.
    Cullen, Grace
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer
    Tuttle, R. Michael
    Brose, Marcia S.
    Grande, Enrique
    Kim, Sun Wook
    Tahara, Makoto
    Sabra, Mona M.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 31 (03) : 295 - 305
  • [38] Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)
    Gianoukakis, Andrew G.
    Mathias, Elton
    Dutcus, Corina E.
    Young, Louise
    Kalantari, Parmida
    Yoon, Steve
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 68 - 68
  • [39] Response to Lenvatinib treatment in patients with Radioiodine-refractory Differentiated Thyroid Cancer (RR-DTC)
    Gianoukakis, A. G.
    Mathias, E.
    Dutcus, C. E.
    Kalantari, P.
    Yoon, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 307
  • [40] Effect of furosemide on whole-body radioactivity retention in patients treated with radioiodine (RAI) for differentiated thyroid cancer (DTC)
    Criscuoli, B.
    Rossi, G.
    Follacchio, G.
    Manni, C.
    Castagnoli, H.
    Fattori, S.
    Capoccetti, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S148 - S148
12345